Subject Areas on Research
- AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
- Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
- BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
- Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
- Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.
- Increased expression of Drosophila tetraspanin, Tsp68C, suppresses the abnormal proliferation of ytr-deficient and Ras/Raf-activated hemocytes.
- Reelin signals survival through Src-family kinases that inactivate BAD activity.
- Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
- Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
- The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
- The importance of the Erk pathway in the development of linker for activation of T cells-mediated autoimmunity.
- Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.
- Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.
- Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Keywords of People